BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35544603)

  • 1. Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion.
    Zhang M; Zhang H; Li Z; Bai L; Wang Q; Li J; Jiang M; Xue Q; Cheng N; Zhang W; Mao D; Chen Z; Huang J; Meng G; Chen Z; Chen SJ
    Blood; 2022 Sep; 140(12):1390-1407. PubMed ID: 35544603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
    Gu Z; Churchman M; Roberts K; Li Y; Liu Y; Harvey RC; McCastlain K; Reshmi SC; Payne-Turner D; Iacobucci I; Shao Y; Chen IM; Valentine M; Pei D; Mungall KL; Mungall AJ; Ma Y; Moore R; Marra M; Stonerock E; Gastier-Foster JM; Devidas M; Dai Y; Wood B; Borowitz M; Larsen EE; Maloney K; Mattano LA; Angiolillo A; Salzer WL; Burke MJ; Gianni F; Spinelli O; Radich JP; Minden MD; Moorman AV; Patel B; Fielding AK; Rowe JM; Luger SM; Bhatia R; Aldoss I; Forman SJ; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Loh ML; Hunger SP; Mullighan CG
    Nat Commun; 2016 Nov; 7():13331. PubMed ID: 27824051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characteristics of
    Ohki K; Kiyokawa N; Saito Y; Hirabayashi S; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fukushima K; Hasegawa D; Fukushima H; Imai M; Kajiwara R; Koike T; Komori I; Matsui A; Mori M; Moriwaki K; Noguchi Y; Park MJ; Ueda T; Yamamoto S; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Takahashi H; Fukushima T; Hayashi Y; Koh K; Manabe A; Ohara A;
    Haematologica; 2019 Jan; 104(1):128-137. PubMed ID: 30171027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
    Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
    Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.
    Hirano D; Hayakawa F; Yasuda T; Tange N; Yamamoto H; Kojima Y; Morishita T; Imoto N; Tsuzuki S; Mano H; Naoe T; Kiyoi H
    Oncogene; 2019 Mar; 38(13):2263-2274. PubMed ID: 30478446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
    Suzuki K; Okuno Y; Kawashima N; Muramatsu H; Okuno T; Wang X; Kataoka S; Sekiya Y; Hamada M; Murakami N; Kojima D; Narita K; Narita A; Sakaguchi H; Sakaguchi K; Yoshida N; Nishio N; Hama A; Takahashi Y; Kudo K; Kato K; Kojima S
    J Clin Oncol; 2016 Oct; 34(28):3451-9. PubMed ID: 27507882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia.
    Zhang M; Mao D; Zhang W
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1331-1336. PubMed ID: 29408457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia.
    Prima V; Gore L; Caires A; Boomer T; Yoshinari M; Imaizumi M; Varella-Garcia M; Hunger SP
    Leukemia; 2005 May; 19(5):806-13. PubMed ID: 15744350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
    Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
    Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.
    Tsuzuki S; Yasuda T; Kojima S; Kawazu M; Akahane K; Inukai T; Imaizumi M; Morishita T; Miyamura K; Ueno T; Karnan S; Ota A; Hyodo T; Konishi H; Sanada M; Nagai H; Horibe K; Tomita A; Suzuki K; Muramatsu H; Takahashi Y; Miyazaki Y; Matsumura I; Kiyoi H; Hosokawa Y; Mano H; Hayakawa F
    Blood Cancer Discov; 2020 Jul; 1(1):82-95. PubMed ID: 34661142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification, crystallization, and X-ray diffraction analysis of myocyte enhancer factor 2D and DNA complex.
    Chen Z; Wang Q; Zhang H; Ma X; Wu W; Cheng N; Zhang J; Zhou A; Li Y; Meng G
    Protein Expr Purif; 2021 Mar; 179():105788. PubMed ID: 33221504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel
    Van Outersterp I; Hormann FM; Hoogkamer AQ; Boeree A; Van den Broek SA; Den Boer ML; Boer JM
    Haematologica; 2023 Oct; 108(10):2859-2864. PubMed ID: 37051743
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Sadras T; Müschen M
    Blood Cancer Discov; 2020 Jul; 1(1):18-20. PubMed ID: 34661138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEF2D-BCL9 B-Lymphoblastic Leukemia Blast Morphology Does Not Always Mimic Mature B-Cell Leukemia.
    Baek HJ; Choi YJ; Kim BR; Lee JH; Shin MG; Kook H
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):112-113. PubMed ID: 33235148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.
    Akahane K; Yasuda T; Tsuzuki S; Hayakawa F; Kiyokawa N; Somazu S; Watanabe A; Kagami K; Abe M; Harama D; Goi K; Kawazu M; Kojima S; Imamura T; Goto H; Iwamoto S; Minegishi M; Abe M; Hojo H; Inaba T; Mano H; Sugita K; Inukai T
    Hematol Oncol; 2020 Oct; 38(4):614-617. PubMed ID: 32515032
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.
    Li JF; Dai YT; Lilljebjörn H; Shen SH; Cui BW; Bai L; Liu YF; Qian MX; Kubota Y; Kiyoi H; Matsumura I; Miyazaki Y; Olsson L; Tan AM; Ariffin H; Chen J; Takita J; Yasuda T; Mano H; Johansson B; Yang JJ; Yeoh AE; Hayakawa F; Chen Z; Pui CH; Fioretos T; Chen SJ; Huang JY
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11711-E11720. PubMed ID: 30487223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13).
    Yuki Y; Imoto I; Imaizumi M; Hibi S; Kaneko Y; Amagasa T; Inazawa J
    Cancer Sci; 2004 Jun; 95(6):503-7. PubMed ID: 15182431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and outcomes of fusion gene defined adult Ph-negative B-cell precursor acute lymphoblastic leukemia patients: A single institutional report.
    Sun K; Wang J; Chen WM; Xu N; Long LY; Wang X; Jiang H; Jiang Q; Huang XJ; Qin YZ
    Biomol Biomed; 2023 Mar; 23(2):298-309. PubMed ID: 36124444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16.
    Ohki K; Takahashi H; Fukushima T; Nanmoku T; Kusano S; Mori M; Nakazawa Y; Yuza Y; Migita M; Okuno H; Morimoto A; Yoshino H; Kato M; Hayashi Y; Manabe A; Ohara A; Hasegawa D; Inukai T; Tomizawa D; Koh K; Kiyokawa N;
    Genes Chromosomes Cancer; 2020 Oct; 59(10):551-561. PubMed ID: 32368831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.